PDS Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 25
- Market Cap
- $114.8M
- Website
- http://www.pdsbiotech.com
- Introduction
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
Cancer Immunotherapy Market Research Report 2025-2029
The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.
Promising Advancements in Cancer Treatment Drive Buy Rating for PDS Biotechnology
Joseph Pantginis, H.C. Wainwright analyst, maintains Buy rating on PDS Biotechnology (PDSB) with a $21.00 price target, citing the company's promising cancer treatment advancements, particularly its VERSAMUNE platform and VERSATILE-003 study for HPV-16 positive head and neck cancers, supported by oncology key opinion leaders. Comparisons with KEYNOTE-048 and LEAP-010 highlight PDS’s competitive edge and favorable response rates.
PDS Biotechnology reports inducement grant under Nasdaq listing rule
PDS Biotechnology granted 7,000 nonstatutory stock options to a clinical department employee on Dec 3, 2024, under its 2019 Inducement Plan. Each option has an exercise price of $2.25, vesting over four years.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PDS Biotechnology granted nonstatutory stock options for 7,000 shares at $2.25/share to a new clinical employee, vesting over 4 years under Nasdaq Rule 5635(c)(4) and the 2019 Inducement Plan.
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
PDS Biotechnology (PDSB) declined 35.7% in four weeks, now oversold with RSI at 22.34, suggesting a potential reversal. Analysts raised earnings estimates by 4.9% in 30 days, and PDSB holds a Zacks Rank #2 (Buy), indicating a near-term turnaround.
PDS Biotechnology's (PDSB) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated a buy rating on PDS Biotechnology (NASDAQ:PDSB) with a $21.00 price target. Other analysts have given mixed ratings, resulting in a consensus 'Moderate Buy' with an average target of $12.33. The stock opened at $2.01, with a market cap of $74.01 million. Institutional investors have recently increased their holdings in the company.
PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed PDS Biotechnology's 'buy' rating with a $21.00 target price. Other analysts have varied ratings, resulting in an average 'Moderate Buy' rating and $14.25 target price. The stock traded down to $2.02 with a market cap of $74.38 million.
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial ...
PDS Biotechnology Corp reports a Q3 2024 net loss of $10.7 million, with increased R&D expenses and a solid financial position. The company highlights strong investor interest in the VERSATILE-003 trial and positive data from VERSATILE-002. Despite financial challenges and competitive pressures, PDSB remains focused on HPV16-positive head and neck cancer, with plans to start VERSATILE-003 in Q1 2025.
© Copyright 2025. All Rights Reserved by MedPath